Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

COVID-19 in Lymphangioleiomyomatosis

CHEST Journal(2021)10.1016/j.chest.2021.12.640Source: DataRank Database

COVID-19 in Lymphangioleiomyomatosis is a research paper published in CHEST Journal (2021). On theSindex it has a DataRank of 0. It has been cited 23 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access23 citations

Free full text

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 2.40)OA: greenTopics (30)Linked Datasets (14)DataCite Reuse (14)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (12)

Elżbieta Radzikowska ORCID,Vincent Cottin ORCID,Daniel F. Dilling ORCID,Ali Ataya ORCID,Carlos Roberto Ribeiro de Carvalho ORCID

Live enrichment

PubMed:34942174 OpenAlex:https://openalex.org/W4200076807

National Institutes of Health

Grant: U01HL131755

Ministry of Health, Labour and Welfare

Grant: R34HL138235

National Institutes of Health

Grant: 5R34HL138235-02

Resveratrol and Sirolimus in LAM Trial (RESULT)

National Institutes of Health

Grant: 5U01HL131755-04

Multicenter Interventional Lymphangioleiomyomatosis Early Disease Trial (MILED)-CCC

Medical Research Council

FWCI

2.40

Citation Percentile

0.9%

Citation Trend

2022

2023

2024

2025

greenLicense: Elsevier TDM

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8687712

publisherhttps://api.elsevier.com/content/article/PII:S0012369221051667?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0012369221051667?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.chest.2021.12.640

Fields of Study

Tuberous Sclerosis Complex ResearchInterstitial Lung Diseases and Idiopathic Pulmonary FibrosisPolyomavirus and related diseases0301 basic medicine0303 health sciences03 medical and health sciencesCOVID-19HumansLung NeoplasmsLymphangioleiomyomatosisSirolimusTuberous Sclerosis Complex 2 ProteinTumor Suppressor Proteins

MeSH Terms

Tuberous Sclerosis Complex 2 ProteinCOVID-19HumansLung NeoplasmsLymphangioleiomyomatosisSirolimusTumor Suppressor Proteins

Keywords

MedicineCoronavirus disease 2019 (COVID-19)Lymphangioleiomyomatosis2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VirologyPathologyTuberous sclerosisOutbreakDisease

Sustainable Development Goals

SDG 0: Good health and well-being

Additional file 1 of Safety and efficacy of COVID-19 vaccination in the Chinese population with pulmonary lymphangioleiomyomatosis: a single-center retrospective study

10.6084/m9.figshare.26157215.v1figshare

Additional file 1 of Safety and efficacy of COVID-19 vaccination in the Chinese population with pulmonary lymphangioleiomyomatosis: a single-center retrospective study

10.6084/m9.figshare.26157215figshare

Additional file 2 of Safety and efficacy of COVID-19 vaccination in the Chinese population with pulmonary lymphangioleiomyomatosis: a single-center retrospective study

10.6084/m9.figshare.26157611.v1figshare

Additional file 2 of Safety and efficacy of COVID-19 vaccination in the Chinese population with pulmonary lymphangioleiomyomatosis: a single-center retrospective study

10.6084/m9.figshare.26157611figshare

Additional file 3 of Safety and efficacy of COVID-19 vaccination in the Chinese population with pulmonary lymphangioleiomyomatosis: a single-center retrospective study

10.6084/m9.figshare.26742422.v1figshare

Additional file 3 of Safety and efficacy of COVID-19 vaccination in the Chinese population with pulmonary lymphangioleiomyomatosis: a single-center retrospective study

10.6084/m9.figshare.26742422figshare

Additional file 4 of Safety and efficacy of COVID-19 vaccination in the Chinese population with pulmonary lymphangioleiomyomatosis: a single-center retrospective study

10.6084/m9.figshare.26742425.v1figshare

Additional file 4 of Safety and efficacy of COVID-19 vaccination in the Chinese population with pulmonary lymphangioleiomyomatosis: a single-center retrospective study

10.6084/m9.figshare.26742425figshare

Additional file 5 of Safety and efficacy of COVID-19 vaccination in the Chinese population with pulmonary lymphangioleiomyomatosis: a single-center retrospective study

10.6084/m9.figshare.26742428.v1figshare

Additional file 5 of Safety and efficacy of COVID-19 vaccination in the Chinese population with pulmonary lymphangioleiomyomatosis: a single-center retrospective study

10.6084/m9.figshare.26742428figshare

Additional file 6 of Safety and efficacy of COVID-19 vaccination in the Chinese population with pulmonary lymphangioleiomyomatosis: a single-center retrospective study

10.6084/m9.figshare.26742431.v1figshare

Additional file 6 of Safety and efficacy of COVID-19 vaccination in the Chinese population with pulmonary lymphangioleiomyomatosis: a single-center retrospective study

10.6084/m9.figshare.26742431figshare

Additional file 7 of Safety and efficacy of COVID-19 vaccination in the Chinese population with pulmonary lymphangioleiomyomatosis: a single-center retrospective study

10.6084/m9.figshare.26742434.v1figshare

Additional file 7 of Safety and efficacy of COVID-19 vaccination in the Chinese population with pulmonary lymphangioleiomyomatosis: a single-center retrospective study

10.6084/m9.figshare.26742434figshare